AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows
Shares of Akeso surged after British drug maker AstraZeneca moved to advance the Chinese biotech firm’s flagship cancer drug, while a new deal from US giant Merck further underscored the sector’s global momentum amid easing fears of US curbs. AstraZeneca on Tuesday announced a US$2 billion equity investment in Florida-headquartered Summit Therapeutics, which holds the exclusive rights to develop and commercialise Akeso’s immunotherapy drug ivonescimab outside China. Summit and AstraZeneca…
Exact coordinates
florida: 27.660, -81.520
china: 35.860, 104.200
Read it at South China Morning Post See this on the map
What might happen next? AI-generated
These scenarios are written by an AI language model from the headline and summary above. They are not predictions from the newsroom, and they are not evidence of anything. Every one is given a deadline and checked against later coverage, and the score is published on the ledger — including the ones that miss.
ForecastGeo shows the headline and summary published by the newsroom and places the story on a map. The full article lives at the source.